January 21, 2026 did not arrive quietly. It showed up with intent, with receipts, with a company named Mendra that sounds less like a biotech and more like a verb. To mend what the system keeps...
January 21, 2026 did not arrive quietly. It showed up with intent, with receipts, with a company named Mendra that sounds less like a biotech and more like a verb. To mend what the system keeps breaking. Founded in 2025 and headquartered in San Francisco, Mendra launched out of stealth with an $82 million Series A that was oversubscribed and very much awake. OrbiMed, 8VC, and 5AM Ventures co-led, with Lux Capital and Wing VC in the room. No warm up act. Just straight to the main set.
Mendra exists because rare disease drug development keeps leaving good science stranded on the platform while the train pulls out for business reasons. Programs stall. Capital dries up. Priorities shift. Patients wait. Mendra’s model is blunt and surgical at the same time. Acquire clinically de-risked rare disease assets that never got their moment. Develop them with discipline. Commercialize them with speed. Mend the gap between promise and delivery.
Joshua Grass is not guessing here. Joshua Grass has lived this movie more than once. He led Modis Therapeutics from Series A to a $400 million acquisition by Zogenix in under two years. He then ran Escient Pharmaceuticals through its $750 million acquisition by Incyte in 2024. Before that, fifteen years at BioMarin building and buying rare disease programs at scale. This is not pattern recognition. This is muscle memory.
Lalarukh Haris Shaikh, Ph.D. brings the infrastructure brain. A decade at Palantir Technologies as EVP of Life Sciences and Aerospace will do that. Data orchestration, artificial intelligence systems, clinical complexity, no romance, no fog. Mendra is applying that operating rigor across asset selection, patient identification, trial enrollment, and global market access. Rare disease timelines do not forgive inefficiency. The platform is designed accordingly.
Then there is commercialization, which is where many rare disease stories quietly fall apart. Jeff Ajer spent nearly two decades at BioMarin, scaling revenue from $400 million to more than $2 billion and launching therapies across 79 markets. That experience does not fit neatly on a slide, but it shows up when execution matters.
The $82 million will fuel asset acquisition, platform buildout, and global readiness. No pipeline names yet, and that restraint is telling. Mendra is not selling hope. It is building a machine tuned for timing, regulation, and patients who cannot afford another stalled program.
Mendra is not loud. It is deliberate. In a market where only about five percent of rare diseases have treatments, that deliberateness feels like pressure building. This is one worth watching before the first acquisition even lands.